Active Biotech has entered into an agreement regarding sale of the Company's property - extraordinary general meeting on Apri...
14 3월 2019 - 2:00AM
Lund Sweden,
March 13 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces
that Active Biotech has entered into an agreement regarding sale of
the Company's property Forskaren 1 in Lund, Sweden, with a newly
formed investor collective led by the real estate company Estea AB.
The purchase price amounts to SEK 275 million.
Active Biotech AB (publ)
indirectly owns the property Forskaren 1 in Lund, Sweden. The
property has been on sale for a period of time.
On February 1, 2019, Active
Biotech announced that the Company had received an indicative,
non-binding offer for the property, amounting to SEK 275 million,
from a newly formed investor collective led by the real estate
company Estea AB and that Active Biotech's Board of Directors
supported Estea's offer.
Following completed due-diligence
review and Estea securing financing for the acquisition, Active
Biotech and Estea have entered into an agreement regarding the sale
of the property. The purchase price amounts to SEK 275 million,
which corresponds to the property's book value. Together with the
rights issue of approximately SEK 47 million that was completed in
2018, the proceeds from the sale of the property are expected to
finance the Company's operations under the current business plan.
The property sale entails a capital injection of approximately SEK
70 million.
"We are delighted
that we have agreed with Estea regarding the sale of the property.
The sale entails a capital injection which secures the financing of
the operations going forward", says Helén Tuvesson, CEO of
Active Biotech.
Active Biotech's largest
shareholder, MGA Holding AB, has, on the request of Estea, declared
its willingness to participate with up to 40 percent of Estea's
equity financing. Hence, the sale is conditional on approval by the
shareholders of Active Biotech. An extraordinary general meeting
will be held on April 4, 2019. Notice to attend the meeting is
announced today through a separate press release.
The Board of Directors proposes that the general
meeting approves the sale.
For further information, reference
is made to the Board of Directors' statement as well as the
independent fairness opinion, held available at the Company's
premises at Scheelevägen 22 in Lund, Sweden, and on
www.activebiotech.com.
Lund March 13, 2019
Helén Tuvesson
President & CEO
For further
information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 21 56
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties in development for neurodegenerative
diseases. ANYARA, an immunotherapy, in development for cancer
indications in partnership with NeoTX Therapeutics Ltd.
Furthermore, commercial activities are conducted for the
tasquinimod, paquinimod and SILC projects. Please visit
www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This is information that Active
Biotech AB is obliged to make public pursuant to the EU Market
Abuse Regulation. This information was submitted for publication,
through the agency of the contact person set out above, at 18.00
p.m. CET on March 13, 2019.
AB has agreement regarding sale of
Comp property - EGM April 4, 2019
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024